Is PT-141 safe?
The approved product has a published safety record in one group of people. RECONNECT, in 1,267 premenopausal women over 24 weeks, listed nausea, flushing, and headache, each in 10% or more. The 52-week follow-on in 684 women, where everyone knew they were getting the drug, tracked safety. The Vyleesi label warns that after each dose, blood pressure goes up and heart rate goes down for a short time, usually back to normal within 12 hours. It says people with uncontrolled hypertension (high blood pressure) or known heart disease should not use it. That is the record for the labeled product. It is not a safety table for a research-chemical vial, and not a safety finding in men. This FAQ does not invent a male rate or a research-vial rate. Talk with a clinician about the approved product. Full record at /compounds/pt-141.
Studies in people from the compound pages this answer belongs to
- PT-141
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT) 2019 PMID 31599840
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder 2019 PMID 31599847
- Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide 2017 PMID 27977473
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of sexual health and hormone peptides. PT-141, melanotan, oxytocin, gonadorelin, and kisspeptin-10.